| 1 |
31645655 | Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir. | 2020 Jan |
3 |
| 2 |
31959479 | Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. | 2020 Apr |
2 |
| 3 |
31291311 | Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C. | 2019 |
1 |
| 4 |
29353349 | Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. | 2018 Aug |
4 |
| 5 |
27530469 | Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. | 2017 Feb |
1 |
| 6 |
27798211 | Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat. | 2017 Feb |
1 |
| 7 |
27664109 | A Review of Daclatasvir Drug-Drug Interactions. | 2016 Nov |
2 |
| 8 |
26744738 | Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection. | 2015 Nov |
1 |